Inmune Bio (INMB) Current Leases (2019 - 2026)
Inmune Bio (INMB) posted Current Leases of $704000.0 for Q1 2026, up 13.0% sequentially from $623000.0 in Q4 2025, and up 382.19% YoY from $146000.0 in Q1 2025.
Inmune Bio (INMB) Current Leases (2019 - 2026) Analysis & Trends
Inmune Bio has reported Current Leases for 8 years, with the latest figure at $704000.0 in Q1 2026.
- Quarterly Current Leases rose 382.19% year-over-year to $704000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $704000.0 (up 382.19% YoY) and the FY2025 annual result came in at $623000.0, up 345.0% from the prior year.
- Current Leases grew to $704000.0 in Q1 2026 per INMB's latest filing, from $623000.0 in the prior quarter.
- Over five years, Current Leases peaked at $704000.0 in Q1 2026 and troughed at $82000.0 in Q1 2022.
- A 5-year average of $208117.6 and a median of $130000.0 in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2026: Current Leases tumbled 35.56% in 2022, then jumped 382.19% in 2026.
- Over 5 years, Current Leases stood at $87000.0 in 2022, then jumped by 36.78% to $119000.0 in 2023, then increased by 17.65% to $140000.0 in 2024, then surged by 345.0% to $623000.0 in 2025, then grew by 13.0% to $704000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $704000.0, $623000.0, and $457000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Inmune Bio | 62.12 Mn | 43.71 Mn | - | 812,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 812,000.00 |
| Mar 31, 2026 | 704,000.00 |
| Dec 31, 2025 | 623,000.00 |
| Sep 30, 2025 | 457,000.00 |
| Jun 30, 2025 | 220,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Mar 31, 2024 | 125,000.00 |
| Dec 31, 2023 | 119,000.00 |
| Sep 30, 2023 | 106,000.00 |
| Jun 30, 2023 | 101,000.00 |
| Mar 31, 2023 | 106,000.00 |
| Dec 31, 2022 | 87,000.00 |
| Sep 30, 2022 | 144,000.00 |
| Jun 30, 2022 | 113,000.00 |
| Mar 31, 2022 | 82,000.00 |
| Dec 31, 2021 | 135,000.00 |
| Sep 30, 2021 | 38,000.00 |